The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 10, 2013, Pages 1312-1319

  Vazquez Elizondo, G ^a   Ngamruengphong, S ^a   Khrisna, M ^a   Devault, K R ^a   Talley, N J ^a   Achem, S R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG RESPONSE; ENDOSCOPY; EOSINOPHIL COUNT; EOSINOPHILIC ESOPHAGITIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ENDOSCOPY; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885950244     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12513     Document Type: Article

References (30)

1. Dellon ES,. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012; 10: 1066-78.
2. Ludvigsson JF, Aro P, Walker MM, et al,. Celiac disease, eosinophilic esophagitis and gastroesophageal reflux disease, an adult population-based study. Scand J Gastroenterol 2013; 48: 808-14.
3. Syed AA, Andrews CN, Shaffer E, Urbanski SJ, Beck P, Storr M,. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Aliment Pharmacol Ther 2012; 36: 950-8.
4. Hurrell JM, Genta RM, Dellon ES,. Prevalence of esophageal eosinophilia varies by climate zone in the United States. Am J Gastroenterol 2012; 107: 698-706.
5. Kapel RC, Miller JK, Torres C, Aksoy S, Lash R, Katzka DA,. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology 2008; 134: 1316-21.
6. Straumann A, Simon HU,. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol 2005; 115: 418-9.
7. Furuta GT, Liacouras CA, Collins MH, et al,. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133: 1342-63.
8. Liacouras CA, Furuta GT, Hirano I, et al,. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3-20, e6.
9. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA,. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013; 108: 679-92.
10. Gonsalves N, Policarpio-Nicolas M, Zhang Q, Rao MS, Hirano I,. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006; 64: 313-9.
11. Hirano I,. Editorial: should patients with suspected eosinophilic esophagitis undergo a therapeutic trial of proton pump inhibition? Am J Gastroenterol 2013; 108: 373-5.
12. Spechler SJ, Genta RM, Souza RF,. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007; 102: 1301-6.
13. Rodrigo S, Abboud G, Oh D, et al,. High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. Am J Gastroenterol 2008; 103: 435-42.
14. Ngo P, Furuta GT, Antonioli DA, Fox VL,. Eosinophils in the esophagus-peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia Am J Gastroenterol 2006; 101: 1666-70.
15. Molina-Infante J, Ferrando-Lamana L, Mateos-Rodriguez JM, Perez-Gallardo B, Prieto-Bermejo AB,. Overlap of reflux and eosinophilic esophagitis in two patients requiring different therapies: a review of the literature. World J Gastroenterol 2008; 14: 1463-6.
16. Dubecz A, Mentrikoski M, Peters JH,. Eosinophilic esophagitis with severe GERD. Am J Gastroenterol 2009; 104: 527-9.
17. Molina-Infante J, Ferrando-Lamana L, Fernandez-Bermejo M, Porcel-Carreno S,. Eosinophilic esophagitis in GERD patients: a clinicopathological diagnosis using proton pump inhibitors. Am J Gastroenterol 2009; 104: 2856-7.
18. Dohil R, Newbury RO, Aceves S,. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci 2012; 57: 1413-9.
19. Schroeder S, Capocelli KE, Masterson JC, et al,. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2013; 56: 166-72.
20. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al,. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011; 9: 110-7.
21. Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK,. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009; 154: 96-100.
22. Sayej WN, Patel R, Baker RD, Tron E, Baker SS,. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009; 49: 393-9.
23. Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC,. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010; 55: 1313-9.
24. Moawad FJ, Veerappan GR, Dias JA, Baker TP, Maydonovitch CL, Wong RK,. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013; 108: 366-72.
25. Kedika RR, Souza RF, Spechler SJ,. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 2009; 54: 2312-7.
26. Yoshida N, Yoshikawa T, Tanaka Y, et al,. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000; 14 (Suppl. 1): 74-81.
27. Cortes JR, Rivas MD, Molina-Infante J, et al,. Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. J Allergy Clin Immunol 2009; 124: 607-10, e1.
28. Zhang X, Cheng E, Huo X, et al,. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS ONE 2012; 7: e50037.
29. Cheng E, Zhang X, Huo X, et al,. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 2013; 62: 824-32.
30. Francis DL, Foxx-Orenstein A, Arora AS, et al,. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther 2012; 35: 300-7.